Recombinant Human LDLR Protein, MYC/DDK-tagged, C13 and N15-labeled

• Cat.No.: LDLR-275H
• Product Overview: LDLR MS Standard C13 and N15-labeled recombinant protein (NP_000518) with a C-terminal MYC/DDK tag, was expressed in HEK293 cells.

Specification

• Description: The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Sep 2010]
• Source: HEK293
• Species: Human
• Tag: Myc&DDK
• Molecular Mass: 95.38 kDa
• AA Sequence: MGPWGWKLRWTVALLLAAAGTAVGD RCERNEFQCQDGKCISYKWVCDGSA ECQDGSDESQETCLSVTCKSGDFSC GGRVNRCIPQFWRCDGQVDCDNGSD EQGCPPKTCSQDEFRCHDGKCISRQ FVCDSDRDCLDGSDEASCPVLTCGP ASFQCNSSTCIPQLWACDNDPDCED GSDEWPQRCRGLYVFQGDSSPCSAF EFHCLSGECIHSSWRCDGGPDCKDK SDEENCAVATCRPDEFQCSDGNCIH GSRQCDREYDCKDMSDEVGCVNVTL CEGPNKFKCHSGECITLDKVCNMAR DCRDWSDEPIKECGTNECLDNNGGC SHVCNDLKIGYECLCPDGFQLVAQR RCEDIDECQDPDTCSQLCVNLEGGY KCQCEEGFQLDPHTKACKAVGSIAY LFFTNRHEVRKMTLDRSEYTSLIPN LRNVVALDTEVASNRIYWSDLSQRM ICSTQLDRAHGVSSYDTVISRDIQA PDGLAVDWIHSNIYWTDSVLGTVSV ADTKGVKRKTLFRENGSKPRAIVVD PVHGFMYWTDWGTPAKIKKGGLNGV DIYSLVTENIQWPNGITLDLLSGRL YWVDSKLHSISSIDVNGGNRKTILE DEKRLAHPFSLAVFEDKVFWTDIIN EAIFSANRLTGSDVNLLAENLLSPE DMVLFHNLTQPRGVNWCERTTLSNG GCQYLCLPAPQINPHSPKFTCACPD GMLLARDMRSCLTEAEAAVATQETS TVRLKVSSTAVRTQHTTTRPVPDTS RLPGATPGLTTVEIVTMSHQALGDV AGRGNEKKPSSVRALSIVLPIVLLV FLCLGVFLLWKNWRLKNINSINFDN PVYQKTTEDEVHICHNQDGYSYPSR QMVSLEDDVATRTRPLEQKLISEED LAANDILDYKDDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 3 months from receipt of products under proper storage and handling conditions.
• Storage: Store at -80 centigrade. Avoid repeated freeze-thaw cycles.
• Concentration: 50 μg/mL as determined by BCA
• Storage Buffer: 100 mM glycine, 25 mM Tris-HCl, pH 7.3.

Gene Information

• Gene Name: LDLR low density lipoprotein receptor [ Homo sapiens (human) ]
• Official Symbol: LDLR
• Synonyms: LDLR; low density lipoprotein receptor; low-density lipoprotein receptor; familial hypercholesterolemia; LDL receptor; low-density lipoprotein receptor class A domain-containing protein 3; FH; FHC; LDLCQ2
• Gene ID: 3949
• mRNA Refseq: NM_000527
• Protein Refseq: NP_000518
• MIM: 606945
• UniProt ID: P01130

Reviews

08/11/2020

The LDLR protein stands out for its exceptional quality, making it an excellent choice to meet my experimental requirements.

10/07/2018

Its purity and consistency guarantee reliable and reproducible results, ensuring the reliability of my research outcomes.

03/04/2017

the LDLR protein offers superior quality and reliability, making it a perfect fit for my experimental needs.

Q&As

Are there conditions where upregulation of LDLR might be beneficial?

Yes, conditions where increasing the expression or function of LDLR could potentially aid in reducing circulating LDL cholesterol and minimizing cardiovascular risk.

Are there ongoing research efforts regarding LDLR and its clinical applications?

Yes, research is continually conducted to better understand LDLR-related conditions and to develop more effective treatments, including gene-editing technologies and novel therapies.

What are the clinical implications of LDLR dysfunction?

Dysfunction in LDLR can lead to high levels of LDL cholesterol in the blood, contributing to conditions like familial hypercholesterolemia and an increased risk of heart disease.

How does LDLR impact atherosclerosis?

A dysfunctional LDLR can lead to an accumulation of LDL cholesterol in the arteries, promoting atherosclerosis, the hardening and narrowing of arteries.

What treatment options exist for LDLR-related conditions?

Treatments involve lifestyle changes, cholesterol-lowering medications, and in some cases, gene therapies or specialized medications targeting the LDL receptor.